Hypocitraturia Is an Untoward Side Effect of Synthetic Human Parathyroid Hormone (hPTH) 1-34 Therapy in Hypoparathyroidism That May Increase Renal Morbidity
| Autor: | Craig B. Langman, Beth A Brillante, Alison M. Boyce, Rachel I Gafni, Lori C. Guthrie, Nancy A Yovetich, Michael T. Collins, Robert James |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Side effect business.industry Endocrinology Diabetes and Metabolism Urinary system 030232 urology & nephrology Urology 030209 endocrinology & metabolism medicine.disease Urinary calcium Renal tubular acidosis 03 medical and health sciences 0302 clinical medicine Hypoparathyroidism Medicine Orthopedics and Sports Medicine Hypercalciuria Nephrocalcinosis business Hypocitraturia |
| Zdroj: | Journal of Bone and Mineral Research. 33:1741-1747 |
| ISSN: | 0884-0431 |
| DOI: | 10.1002/jbmr.3480 |
| Popis: | Subcutaneous human parathyroid hormone (hPTH) therapy can effectively manage hypocalcemia in hypoparathyroidism, with varying effects on hypercalciuria. However, little is known about its ability to decrease the renal comorbidities of hypoparathyroidism: nephrocalcinosis (NC), nephrolithiasis (NL), and renal insufficiency. Urinary citrate (Ucit) promotes the solubility of urinary calcium (UCa); hypocitraturia is a risk factor for NC/NL. Twenty-four-hour UCa, Ucit, and UCa/Ucit were determined in 31 hypoparathyroid subjects receiving hPTH 1-34 therapy for up to 5 years. Before hPTH 1-34, the geometric least squares mean UCa was 346 mg/day (normal |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text